Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

PecFent® (fentanyl pectin nasal spray) in Europe, where it is presently available in six countries.  

"As the first and only treatment option in the U.S. offering fentanyl through nasal administration, Lazanda provides clinically proven pain relief to adult cancer patients suffering from breakthrough pain," noted Jeffrey H. Buchalter, chief executive officer of Archimedes Pharma. "The availability of Lazanda also is an exciting milestone for Archimedes Pharma as it marks our first product launch in the U.S. and represents the expansion of the brand from Europe."

Lazanda will be available through a Risk Evaluation and Mitigation Strategy (REMS) program, which is intended to minimize the risk of misuse, abuse, addiction, overdose, and serious complications due to medication errors. Under the Lazanda REMS program, pharmacies, distributors, and health care professionals who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe Lazanda.

About Lazanda® (fentanyl) nasal spray  Lazanda contains fentanyl, which is a Schedule II controlled substance, and uses Archimedes Pharma's patented drug delivery system, PecSys®.  

Lazanda, incorporating PecSys technology, delivers fentanyl in a rapid, but controlled manner and is designed to deliver a fine mist spray to a mucus membrane, in this case the nasal membrane.  Each spray of Lazanda forms a gel when it contacts the nasal mucosa; the active ingredient is then rapidly absorbed across the mucus membrane and directly into the blood stream.

The efficacy of Lazanda for the management of breakthrough pain in adult cancer patients was established in a double-blind, placebo-controlled clinical study in patients receiving opioid therapy for background pain, in which Lazanda showed a statistically significant improvement compared with placebo on the primary endpoint, the sum of the pain intensity differ
'/>"/>

SOURCE Archimedes Pharma Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
5. Novo Nordisk A/S: PharmaVitae Profile
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)... 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... update and report second quarter 2014 financial results before ... 1, 2014. That same day, Arena will host a ... (5:30 a.m. Pacific Time). The conference ... callers and 914.495.8552 for international callers. Please specify to ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... 2012    Octapharma USA has submitted its Biological License ... Food and Drug Administration (FDA) with the goal of ... 2012. The FDA will evaluate the octaplasLG® ... patients who require replacement of multiple plasma coagulation factors. The ...
... 27, 2012  Ventana Medical Systems, Inc. (Ventana), a member of ... Food and Drug Administration (FDA) for the VENTANA Companion ... VENTANA iScan Coreo Au scanner running ... offering an FDA cleared Ki-67 image analysis algorithm for ...
Cached Medicine Technology:Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 2Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 3Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications 2
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... July 25, 2014 Merrill Corporation ... technology-enabled services for the financial, legal, healthcare and ... data room business, Merrill DataSite, has been recognized ... by GrowthBusiness at the M&A Awards 2014 event. ... achievements of entrepreneurs, management teams, advisors and financiers ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... nearly 27,000 older adults on five continents found that ... on a simple test that measures how fast people ... tested positive for pre-dementia were twice as likely as ... led by scientists at Albert Einstein College of ... Center , was published online on July 16, 2014 ...
(Date:7/25/2014)... July 25, 2014 As thousands of ... U.S. courts, Bernstein Liebhard LLP notes that the Food ... the consumer advocacy group, Public Citizen, to order a ... letter dated May 1, 2014, and released to the ... petition for a ban on the marketing of all ...
Breaking Medicine News(10 mins):Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4
... known as a common marker of inflammation plays a key ... by Cell Press in the September issue of the journal ... for cancer treatment. , CRP is a protein that is ... of inflammation in response to the inflammatory cytokine IL-6. The ...
... in the skull that detects oncoming seizures, then delivers a ... under study at the Medical College of Georgia. , MCG ... determine if the neurostimulator device can help patients whose seizures ... monitors electrical activity of the brain, gets accustomed to what ...
... Most Parents Take "Wait and See" Approach to ... Schwab Learning,a nonprofit program of the Charles ... children with learning and attention problems,announced today their ... who,suspect their child may have a learning problem. ...
... COLUMBIA, S.C., Sept. 10 Harvard Medical School,researchers ... an,innovation that allows health care providers to obtain ... the pre-certification,process more efficient and less costly. ... Care Policy,selected BlueCross, "Web Precert" tool as one ...
... face time with P&G executives ... and the chance to win $40,000 -, BOSTON, ... to create a buzz for the billion dollar,brand. Known throughout the ... Braun is seeking marketing plans,for its electric shaver business from students ...
... much of their time in the womb bobbing along ... from the Georgia Institute of Technology and Emory University ... under similarly shaky conditions. , Georgia Tech and Emory ... embryonic stem cells in fluid environments, similar to shaking ...
Cached Medicine News:Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Implantable device designed to detect, stop seizures under study at MCG 2Health News:Schwablearning.Org Launches Interactive Tool to Help Parents of Children Struggling in School 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 3Health News:Braun Challenges Business School Talent To 'Create A Buzz' 2Health News:Embryonic stem cells thrive when shaken 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: